Protagonist Therapeutics (PTGX) Return on Sales (2017 - 2026)

Protagonist Therapeutics has disclosed Return on Sales across 10 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02% (changed 0.0% YoY), and the FY2025 annual result was 0.03%, down 3.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at Protagonist Therapeutics, up from 0.06% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 73.98% in Q3 2023 to a low of 1.67% in Q1 2023.
• The 5-year median for Return on Sales is 0.01% (2024), against an average of 9.52%.
• Across the five-year window, Return on Sales surged 7401 bps in 2023 and tumbled 7405 bps in 2024, its largest moves.
• Protagonist Therapeutics' Return on Sales stood at 18.03% in 2022, then plunged by 100 bps to 0.03% in 2023, then sank by 133 bps to 0.01% in 2024, then plunged by 567 bps to 0.06% in 2025, then surged by 101 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.06% (Q4 2025), and 0.08% (Q3 2025), per Business Quant data.